Holen Sie sich die Stockscreener-App
4.02
4.51%
-0.19
Handel nachbörslich:
4.02
Schlusskurs vom Vortag:
$4.21
Offen:
$4.2
24-Stunden-Volumen:
1.24M
Relative Volume:
0.79
Marktkapitalisierung:
$639.01M
Einnahmen:
$400.57M
Nettoeinkommen (Verlust:
$9.21M
KGV:
-0.6656
EPS:
-6.04
Netto-Cashflow:
$146.36M
1W Leistung:
-15.90%
1M Leistung:
-8.64%
6M Leistung:
-37.96%
1J Leistung:
-58.90%
1-Tages-Spanne:
$3.985
$4.20
1-Wochen-Bereich:
$3.96
$4.855
52-Wochen-Spanne:
$3.79
$15.70
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
Firmenname
Ironwood Pharmaceuticals Inc
Sektor
Telefon
617-621-7722
Adresse
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Vergleichen Sie IRWD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| IRWD | 4.02 | 639.01M | 400.57M | 9.21M | 146.36M | -6.04 |
| ZTS | 176.42 | 79.51B | 9.15B | 2.43B | 2.31B | 4.92 |
| TAK | 13.53 | 42.89B | 30.27B | 1.93B | 3.45B | 0.444 |
| HLN | 9.43 | 42.57B | 14.26B | 1.55B | 0 | 0.3327 |
| TEVA | 16.49 | 18.51B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.00 | 15.37B | 15.24B | -646.50M | 1.88B | 1.53 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-01-17 | Eingeleitet | Craig Hallum | Buy |
| 2023-12-14 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-09 | Eingeleitet | Jefferies | Buy |
| 2023-09-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-09-02 | Eingeleitet | CapitalOne | Overweight |
| 2022-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2020-09-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-06-17 | Eingeleitet | Northland Capital | Outperform |
| 2019-07-10 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-03-27 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2019-02-25 | Hochstufung | H.C. Wainwright | Sell → Neutral |
| 2019-01-24 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2018-11-07 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2018-11-07 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-07-23 | Eingeleitet | H.C. Wainwright | Sell |
| 2018-05-09 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2018-01-05 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2017-12-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2017-07-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2017-05-03 | Eingeleitet | Wells Fargo | Outperform |
| 2017-04-07 | Bestätigt | Mizuho | Buy |
| 2017-02-22 | Bestätigt | Barclays | Equal Weight |
| 2016-11-04 | Bestätigt | Mizuho | Buy |
| 2016-10-24 | Bestätigt | Wedbush | Neutral |
| 2016-10-10 | Bestätigt | Mizuho | Buy |
| 2016-09-27 | Bestätigt | WallachBeth | Hold |
Alle ansehen
Ironwood Pharmaceuticals Inc Aktie (IRWD) Neueste Nachrichten
Ironwood Pharmaceuticals, Inc. Announces Resignation of Andrew Davis as Senior Vice President and Chief Business Officer, Effective November 22, 2024 - Marketscreener.com
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives $10.40 Consensus PT from Analysts - Defense World
ARMISTICE CAPITAL, LLC Acquires Significant Stake in Ironwood Ph - GuruFocus.com
GSA Capital Partners LLP Purchases 232,087 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - MarketBeat
Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference - Business Wire
Ironwood Pharmaceuticals executive resigns - Investing.com India
Ironwood Pharmaceuticals executive resigns By Investing.com - Investing.com UK
Ironwood Pharmaceuticals Reports Third Quarter 2024 Results and Recent Business Performance - Defense World
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Lowered to “Buy” Rating by StockNews.com - Defense World
Creative Planning Increases Stock Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - Defense World
Ironwood Pharmaceuticals (NASDAQ:IRWD) Cut to Buy at StockNews.com - MarketBeat
Ironwood's Q3 Earnings Lag Estimates, Revenues Top, Stock Down - MSN
What is Leerink Partnrs’ Estimate for IRWD FY2024 Earnings? - Defense World
FY2024 Earnings Forecast for IRWD Issued By Leerink Partnrs - MarketBeat
Robeco Institutional Asset Management B.V. Raises Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Posts Quarterly Earnings Results - MarketBeat
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q3 2024 Earnings Call Transcript - Insider Monkey
Ironwood Pharmaceuticals Inc (IRWD) Q3 2024 Earnings Call Highli - GuruFocus.com
Ironwood Pharmaceuticals Inc (IRWD) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ... - Yahoo Finance
Earnings call: Ironwood Pharmaceuticals reports robust LINZESS demand By Investing.com - Investing.com Canada
Ironwood: Q3 Earnings Snapshot - Houston Chronicle
Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Gap DownTime to Sell? - MarketBeat
Ironwood Pharmaceuticals (IRWD) Misses Q3 Earnings Estimates - Yahoo Finance
Ironwood Pharmaceuticals Q3 Earnings: Revenue Beats at $91.59M, EPS Misses at $0.02 - GuruFocus.com
Ironwood Pharmaceuticals Reports Third Quarter 2024 Results - StockTitan
Ironwood Pharmaceuticals Inc (IRWD) Q3 2024 Earnings Report Prev - GuruFocus.com
Ironwood Pharmaceuticals Inc (IRWD) Q3 2024 Earnings Report Preview: What To Expect - Yahoo Finance
StockNews.com Upgrades Ironwood Pharmaceuticals (NASDAQ:IRWD) to Strong-Buy - Defense World
Ironwood Pharmaceuticals (IRWD) Sees Stock Surge Amid Positive A - GuruFocus.com
Ironwood Pharmaceuticals Announces Agreement with Teva Involving LINZESS® (linaclotide) 72 mcg Dosage Strength - Marketscreener.com
Vanguard Group Inc's Strategic Acquisition in Ironwood Pharmaceu - GuruFocus.com
Ironwood Pharmaceuticals (NASDAQ:IRWD) Upgraded at StockNews.com - MarketBeat
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares Sold by Allspring Global Investments Holdings LLC - Defense World
Emerald Advisers LLC Has $1.88 Million Stock Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - MarketBeat
Where Are They Now? Ironwood Pharmaceuticals - Life Science Leader Magazine
Ironwood Pharmaceuticals (IRWD) Scheduled to Post Earnings on Thursday - MarketBeat
What Do Analysts Think About Ironwood Pharmaceuticals Inc’s (NASDAQ:IRWD) Future? - Stocks Register
Short Bowel Syndrome Market to Show Remarkable Growth Trends - openPR
Ironwood Pharmaceuticals (NASDAQ:IRWD) Trading 9.1% HigherHere's What Happened - MarketBeat
Ironwood Pharmaceuticals Shares Rise 10% on Positive Results in Bowel Disease Study - MarketWatch
Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2 - Business Wire
Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews
Applied Therapeutics (NASDAQ:APLT) versus Ironwood Pharmaceuticals (NASDAQ:IRWD) Head-To-Head Analysis - Defense World
Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call - Business Wire
Lacklustre Performance Is Driving Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Low P/S - Simply Wall St
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Down 4.8%What's Next? - MarketBeat
Exchange Traded Concepts LLC Takes Position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - Defense World
Financial Survey: Regulus Therapeutics (NASDAQ:RGLS) & Ironwood Pharmaceuticals (NASDAQ:IRWD) - Defense World
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Zacks Research Has Negative Outlook for IRWD FY2025 Earnings - Defense World
Finanzdaten der Ironwood Pharmaceuticals Inc-Aktie (IRWD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.79%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):